Study Shows iCAD Solution Identifies Difficult to Detect Breast Cancers

Study Shows iCAD Solution Identifies Difficult to Detect Breast
Cancers
-- iCAD Second Look System Helps Generate Study Data -- 


NASHUA, N.H., March 29  /PRNewswire-FirstCall/ -- iCAD(R), Inc. (NASDAQ: ICAD),
an industry-leading provider of Computer-Aided Detection (CAD) solutions for
the early detection of cancer, today announced that the Company's Second
Look(R) system was used to generate data for "A Computer- Aided Detection
System for the Evaluation of Breast Cancer by Mammographic Appearance and
Lesion Size" study recently featured in the March 2005 edition of the American
Journal of Roentgenology.

Conducted by Dr. Rachel F. Brem, director of Breast Imaging at George
Washington University in Washington DC, the study was devised to evaluate CAD
performance in the detection of breast cancer based on appearance and size.
Report findings conclude that CAD systems effectively help to detect breast
cancers a radiologist may be more apt to initially miss.

Small lesions are very challenging for the radiologist to detect, reported Dr.
Brem, lead author of the study. The study of 201 women found that "CAD was
highly effective in detecting even the smallest lesions, with a sensitivity of
92% for lesions of 5 mm or less."  Findings also illustrate that CAD was most
effective in detecting cancers measuring 11-15 mm (94%). They also reported
that CAD can effectively detect "cancers smaller than or equal to 1 cm have a
better prognosis than cancers greater than 1 cm," and therefore are important
to detect.

Subtle masses are also difficult to detect, Dr. Brem said. The study found that
CAD had a sensitivity of 83% for the smallest masses (those measuring 1-5 mm).
It was most sensitive for masses 11-15 mm (91%) and least sensitive for larger
masses measuring greater than 20 mm (75%). This is because CAD is developed to
detect smaller masses as cancers greater than 20 mm should be more readily
detected by a radiologist.

CAD systems assist the radiologist by "processing the breast films, using
algorithms to detect suspicious areas and highlighting those areas," stated Dr.
Brem. This study shows that CAD can help in the most difficult-to-detect cases.
CAD prompts the radiologist to re-examine the films, and the radiologist
decides whether "true areas of concern are present at the highlighted locations
before making the final diagnosis," she continued.

"When CAD is used as a prompt for the radiologist to identify potential areas
of abnormality on the mammogram...it is a useful tool for the improved
detection of breast cancer, regardless of the size of the cancer," Dr. Brem
concludes.

"As a strong proponent of medical research, iCAD was honored to take part in a
study that proved how CAD positively impacts breast cancer prognosis," said
Scott Parr, CEO at iCAD. "This study demonstrates the life-saving impact and
potential our industry-leading CAD solutions offer."

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD)
solutions that enable healthcare professionals to better serve patients by
identifying pathologies and pinpointing cancer earlier. Recipient of Frost &
Sullivan's Growth Strategy Leadership award and repeatedly recognized as
offering "The Winning Combination" of Price and Performance by MD Buyline, iCAD
offers a comprehensive range of high-performance, upgradeable CAD systems for
the high, mid and low volume mammography markets. As the most frequently
selected CAD solution for film-based and digital breast screening, iCAD is
entrusted with the task of early cancer detection by almost one thousand
women's healthcare centers worldwide. For more information, call +1 866 iCADnow
or visit http://www.icadmed.com/.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995:

Certain statements contained in this News Release constitute "forward- looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995.  Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements.  Such factors include, but are not limited to, the
risks of uncertainty of patent protection, the impact of supply and
manufacturing constraints or difficulties, product market acceptance, possible
technological obsolescence, increased competition, customer concentration and
other risks detailed in the Company's other filings with the Securities and
Exchange Commission.  The words "believe", "demonstrate", "intend", "expect",
"estimate", "anticipate", "likely", and similar expressions identify forward-
looking statements.  Readers are cautioned not to place undue reliance on those
forward-looking statements, which speak only as of the date the statement was
made.  The Company is under no obligation to provide any updates to any
information contained in this release.

For more information on iCAD, Inc., contact Kevin McGrath of Cameron Associates
at [phone] or via email at . 

DATASOURCE: iCAD, Inc.



CONTACT: Kevin McGrath of Cameron Associates, [phone],





Web site:  http://www.icadmed.com/ 

Copyright